Tislelizumab Approved by FDA For Unresectable or Metastatic Pretreated ESCC
March 14th 2024Tislelizumab-jsgr (Tevimbra) has been approved for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) among adult patients who have previously received systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.